The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 524 KB) and Technical Notes (PDF, 756 KB) pages.


Download and Print: Download Printer-friendly PDF Download data

Table 19.29

All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Both Sexes, 2006-2012
Site All Ages Ages 0-19 Ages 20-64 Ages 65+
Count Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval
Low High Low High Low High Low High
Lymphoid Neoplasm 175,423 69.9 69.6 70.1 90.1 89.4 90.7 77.3 77.0 77.7 59.4 58.9 59.9
1 Hodgkin Lymphoma 14,954 86.2 85.6 86.9 96.9 95.8 97.6 90.2 89.5 90.9 54.3 51.3 57.3
2 Non-Hodgkin lymphoma 156,176 68.7 68.4 69.1 88.2 87.4 89.0 75.7 75.3 76.1 60.1 59.6 60.7
2(a) Non-Hodgkin lymphoma, B-cell 144,111 69.1 68.8 69.4 88.8 87.8 89.6 76.5 76.1 76.9 60.7 60.1 61.2
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell 7,914 68.6 67.4 69.8 88.4 87.3 89.4 38.9 36.5 41.3 17.3 13.7 21.2
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell 129,173 69.2 68.8 69.5 89.9 87.8 91.7 78.0 77.6 78.4 60.9 60.4 61.5
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma 30,939 78.4 77.6 79.1 - - - 86.7 85.8 87.5 72.6 71.5 73.7
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma 27,182 81.5 80.7 82.3 - - - 89.6 88.7 90.4 76.1 74.9 77.2
2(a) 2.1.2. Prolymphocytic leukemia, B-cell 97 43.2 29.8 55.9 - - - 52.8 31.9 70.0 37.0 20.6 53.6
2(a) 2.1.3. Mantle-cell lymphoma 3,660 55.9 53.6 58.1 - - - 68.3 65.3 71.0 45.5 42.2 48.6
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglubulinemia 2,806 82.0 79.4 84.4 - - - 89.8 87.0 92.0 77.2 73.3 80.6
2(a) 2.2.1. Lymphoplasmacytic lymphoma 1,273 77.7 73.6 81.2 - - - 85.3 80.6 89.0 72.7 66.8 77.8
2(a) 2.2.2. Waldenstrom macroglubulinemia 1,533 85.7 82.1 88.6 - - - 93.2 89.5 95.6 80.9 75.5 85.2
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL) 33,755 62.0 61.3 62.6 88.3 84.7 91.0 71.2 70.4 72.0 52.5 51.4 53.6
2(a) 2.3.1. DLBCL, NOSc 33,322 61.8 61.2 62.5 89.2 85.6 91.9 71.1 70.2 71.9 52.5 51.4 53.6
2(a) 2.3.2. Intravascular large B-cell lymphoma 54 51.3 33.4 66.5 - - - 59.2 35.1 76.9 44.2 20.7 65.5
2(a) 2.3.3. Primary effusion lymphoma 54 23.1 11.6 37.0 - - - 23.8 11.1 39.1 - - -
2(a) 2.3.4. Mediastinal large B-cell lymphoma 325 83.9 78.1 88.2 69.4 43.8 85.1 86.8 81.0 90.9 - - -
2(a) 2.4. Burkitt lymphoma/leukemia 2,202 60.2 57.9 62.4 89.7 86.4 92.1 56.9 53.9 59.7 36.4 30.4 42.5
2(a) 2.5. Marginal-zone lymphoma (MZL) 9,414 89.7 88.5 90.8 98.5 89.7 99.8 93.1 91.9 94.2 86.3 84.2 88.2
2(a) 2.5.1. Splenic MZL 831 85.6 80.8 89.2 - - - 85.6 79.8 89.8 85.4 78.1 90.4
2(a) 2.5.2. Extranodal MZL, MALTc type 5,667 93.9 92.4 95.1 97.8 85.0 99.7 96.0 94.6 97.0 91.6 88.6 93.9
2(a) 2.5.3. Nodal MZL 2,916 82.7 80.3 84.8 - - - 88.9 86.2 91.1 77.4 73.6 80.7
2(a) 2.6. Follicular lymphoma 17,971 87.5 86.7 88.2 97.3 80.1 99.7 91.7 90.9 92.4 81.6 80.0 83.1
2(a) 2.7. Hairy-cell leukemia 1,511 92.6 89.9 94.5 - - - 96.8 94.6 98.1 81.4 73.4 87.2
2(a) 2.8. Plasma cell neoplasms 30,545 48.4 47.6 49.2 - - - 61.4 60.3 62.5 38.1 37.1 39.2
2(a) 2.8.1. Plasmacytoma 1,893 66.8 63.7 69.6 - - - 77.9 74.4 81.0 51.4 46.0 56.4
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia 28,652 47.2 46.4 48.0 - - - 60.0 58.8 61.1 37.5 36.4 38.6
2(a) 2.9. Heavy chain disease 30 59.8 34.0 78.3 - - - - - - - - -
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOSc 7,024 68.4 66.8 70.0 92.7 83.1 96.9 76.2 74.1 78.1 63.2 60.8 65.5
2(b) Non-Hodgkin lymphoma, T-cell 10,585 65.1 63.9 66.2 86.5 84.3 88.4 68.4 67.0 69.7 51.4 49.0 53.8
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell 498 66.1 61.6 70.2 87.5 82.6 91.1 50.1 43.0 56.7 7.5 1.3 21.2
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell 10,034 65.2 64.0 66.3 86.2 83.6 88.4 69.3 67.9 70.7 52.1 49.7 54.5
2(b) 2.1. Mycosis fungoides/Sezary syndrome 2,507 90.1 87.9 91.9 94.8 76.6 98.9 92.1 89.9 93.8 85.5 79.6 89.8
2(b) 2.1.1. Mycosis fungoides 2,429 91.7 89.5 93.5 94.8 76.6 98.9 93.0 90.8 94.7 88.7 82.5 92.8
2(b) 2.1.2. Sezary syndrome 78 35.9 21.2 50.8 - - - 47.8 26.8 66.2 20.8 4.6 44.8
2(b) 2.2. Peripheral T-cell lymphoma 5,623 57.7 56.0 59.2 83.6 78.4 87.7 65.1 63.2 67.0 43.5 40.7 46.3
2(b) 2.2.1. Peripheral T-cell lymphoma, NOSc 1,928 38.9 36.2 41.5 69.5 52.3 81.6 46.0 42.4 49.5 28.5 24.4 32.6
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma 753 43.7 39.3 48.0 - - - 55.4 49.0 61.3 34.2 28.3 40.2
2(b) 2.2.3. Subcutaneous panniculitis- like T-cell lymphoma 74 88.4 76.9 94.4 - - - 88.8 73.2 95.6 - - -
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type 1,145 59.6 56.2 62.8 84.9 78.1 89.7 65.0 60.9 68.8 30.9 23.8 38.2
2(b) 2.2.5. Hepatosplenic T-cell lymphoma 52 26.6 14.4 40.5 - - - 29.0 14.4 45.3 - - -
2(b) 2.2.6. Enteropathy-type T-cell lymphoma 59 13.2 4.6 26.6 - - - 8.8 0.9 28.3 16.6 3.6 37.7
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOSc 1,088 83.8 80.3 86.7 96.2 75.5 99.5 88.1 84.3 91.0 76.3 70.0 81.4
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma 524 89.5 84.5 93.0 - - - 95.1 90.7 97.4 78.0 65.1 86.6
2(b) 2.3. Adult T-cell leukemia/lymphoma 1,210 62.0 58.5 65.2 86.7 83.4 89.4 41.0 35.0 46.9 14.8 7.4 24.7
2(b) 2.4. NKc/T-cell lymphoma, nasal-type/ agressive NKc-cell leukemia 435 43.2 37.6 48.7 - - - 43.4 37.2 49.4 39.1 26.3 51.6
2(b) 2.5. T-cell large granular lymphocytic leukemia 99 68.8 56.6 78.3 - - - 78.8 62.7 88.5 57.8 39.4 72.4
2(b) 2.6. Prolymphocytic leukemia, T-cell 160 13.6 7.1 22.4 - - - 18.3 8.9 30.3 9.0 1.9 22.9
2(b) 3. Non-Hodgkin lymphoma, NOSc , T-cell 53 38.1 24.8 51.4 - - - 51.0 31.8 67.3 - - -
2(c) Non-Hodgkin lymphoma, unknown lineage 1,480 59.4 56.5 62.2 86.2 82.1 89.4 57.5 52.7 62.0 44.1 39.1 49.0
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage 609 65.0 60.9 68.8 86.5 82.4 89.7 39.4 31.1 47.6 21.7 13.5 31.2
2(c) 2. Prolymphocytic leukemia, unknown lineage 44 51.2 34.1 66.0 - - - - - - 42.2 23.1 60.1
2(c) 3. Non-Hodgkin lymphoma, NOSc, unknown lineage 827 55.6 51.5 59.6 - - - 65.1 59.4 70.3 48.3 42.5 53.9
2(*) 1. Total precursor lymphoma/leukemiad 9,021 68.3 67.2 69.3 88.3 87.3 89.3 40.1 38.0 42.3 17.8 14.6 21.3
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma 117 67.8 55.4 77.5 - - - 77.9 64.1 86.9 44.6 20.8 65.9
4 Lymphoid neoplasm, NOSc 4,176 50.0 48.0 51.9 84.6 73.2 91.4 61.9 59.1 64.5 41.0 38.3 43.7

Footnotes:

a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.